{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:21:06Z","timestamp":1760235666799,"version":"build-2065373602"},"reference-count":99,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The 21st annual Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC) was held in Calgary, Alberta, 20\u201321 September 2019. The WCGCCC is an interactive multi-disciplinary conference attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists, pathologists, radiologists, and allied health care professionals such as dietitians and nurses participated in presentation and discussion sessions to develop the recommendations presented here. This consensus statement addresses current issues in the management of hepato-pancreato-biliary (HPB) cancers.<\/jats:p>","DOI":"10.3390\/curroncol28050310","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T08:04:23Z","timestamp":1632211463000},"page":"3629-3648","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Report from the 21st Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; 20\u201321 September 2019"],"prefix":"10.3390","volume":"28","author":[{"given":"Richard","family":"Lee-Ying","sequence":"first","affiliation":[{"name":"Tom Baker Cancer Center, Alberta Health Service, Calgary, AB T2N 4N2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-7695","authenticated-orcid":false,"given":"Osama","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2099-698X","authenticated-orcid":false,"given":"Shahid","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahida","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver F.","family":"Bathe","sequence":"additional","affiliation":[{"name":"Surgical Oncology, Arnie Charbonneau Cancer Institute, Calgary, AB T2N 4Z6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Brunet","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Dawson","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3834-6835","authenticated-orcid":false,"given":"Janine","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Hebbard","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Kasnik","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, Alberta Health Services, Edmonton, AB T5G 1Z2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3847-2583","authenticated-orcid":false,"given":"Christina A.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duc","family":"Le","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8075-3608","authenticated-orcid":false,"given":"Michael K. C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Paul","family":"McGhie","sequence":"additional","affiliation":[{"name":"Department of Oncology, British Columbia Cancer Agency, Victoria, BC V8R 4S1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Mulder","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, Alberta Health Services, Edmonton, AB T5G 1Z2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Renouf","sequence":"additional","affiliation":[{"name":"Department of Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Tam","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Center, Alberta Health Service, Calgary, AB T2N 4N2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Visser","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph P. W.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Doll","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Center, Alberta Health Service, Calgary, AB T2N 4N2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2018.12.013","article-title":"Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma","volume":"131","author":"Kim","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs. sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: A randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/ijcp.12352","article-title":"GIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): Second interim analysis","volume":"68","author":"Lencioni","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2019.37.15_suppl.4004","article-title":"Results of KEYNOTE-240: Phase 3 study of pembrolizumab (Pembro) vs. best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)","volume":"37","author":"Finn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"v874","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate 459: A Randomised, Multi-Center Phase 3 Study of Nivolumab (NIVO) vs. Sorafenib (SOR) as First-Line (1L) Treatment in Patients (pts) with Advanced Hepatocellular Carcinoma","volume":"30","author":"Yau","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"ix186","DOI":"10.1093\/annonc\/mdz446.002","article-title":"IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs. sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"30","author":"Cheng","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_13","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) (2020). Atezolizumab-Bevacizumab HCC\u2014pERC Final Recommendation, CADTH. Available online: https:\/\/cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10217AtezolizumabBevacizumabHCC_fnRec_EC_Post17Nov2020_final.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2021.39.3_suppl.272","article-title":"Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study","volume":"39","author":"Yoo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_15","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) (2021). Unresectable Hepatocellular Carcinoma\u2014Provisional Funding Algorithm, CADTH. Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/ph0003-000_hcc-report-final.pdf."},{"key":"ref_16","first-page":"195","article-title":"Nutrition in Pancreatic Cancer: A Review","volume":"2","author":"Aghdassi","year":"2016","journal-title":"Gastrointest. Tumors"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gilliland, T.M., Villafane-Ferriol, N., Shah, K.P., Shah, R.M., Tran Cao, H.S., Massarweh, N.N., Silberfein, E.J., Choi, E.A., Hsu, C., and McElhany, A.L. (2017). Nutritional and Metabolic Derangements in Pancreatic Cancer and Pancreatic Resection. Nutrients, 9.","DOI":"10.3390\/nu9030243"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.clnu.2017.06.017","article-title":"ESPEN expert group recommendations for action against cancer-related malnutrition","volume":"36","author":"Arends","year":"2017","journal-title":"Clin. Nutr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/CEG.S168266","article-title":"Exocrine pancreatic insufficiency: Prevalence, diagnosis, and management","volume":"12","author":"Capurso","year":"2019","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.dld.2015.06.015","article-title":"Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature","volume":"47","author":"Bartel","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"ref_21","unstructured":"(2020, December 29). SEER Cancer Statistics Factsheets: Pancreas Cancer, Available online: http:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.bjc.6604838","article-title":"Adjuvant 5-fluorouracil and folinic acid vs. observation for pancreatic cancer: Composite data from the ESPAC-1 and -3(v1) trials","volume":"100","author":"Neoptolemos","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: A randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2019.37.15_suppl.4000","article-title":"APACT: Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P\/G) vs. gemcitabine (G) for surgically resected pancreatic adenocarcinoma","volume":"37","author":"Tempero","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.6004\/jnccn.2014.0106","article-title":"Pancreatic adenocarcinoma, version 2.2014: Featured updates to the NCCN guidelines","volume":"12","author":"Tempero","year":"2014","journal-title":"J. Natl. ComPract. Cancer Netw."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"vii33","DOI":"10.1093\/annonc\/mds224","article-title":"Pancreatic adenocarcinoma: ESMO\u2013ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Seufferlein","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.3748\/wjg.v20.i9.2255","article-title":"Management of borderline and locally advanced pancreatic cancer: Where do we stand?","volume":"20","author":"He","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","article-title":"Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement","volume":"16","author":"Callery","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1245\/ASO.2006.08.011","article-title":"Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy","volume":"13","author":"Varadhachary","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1148\/radiol.13131184","article-title":"Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association","volume":"270","author":"Francis","year":"2014","journal-title":"Radiology"},{"key":"ref_37","first-page":"1","article-title":"Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1200\/JCO.2019.37.15_suppl.4137","article-title":"S WOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine\/nab-paclitaxel for resectable pancreatic adenocarcinoma","volume":"37","author":"Sohal","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total Neoadjuvant Therapy with FOLFIRINOX Followed by Individualised Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/bjs.10870","article-title":"Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer","volume":"105","author":"Versteijne","year":"2018","journal-title":"J. Br. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and Surgical Implications of Neoadjuvant Treatment with FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","article-title":"Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial","volume":"14","author":"Mukherjee","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative Chemoradiotherapy versus immediate surgery for Resectable and borderline Resectable pancreatic Cancer: Results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1200\/JCO.2021.39.15_suppl.4016","article-title":"Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial","volume":"39","author":"Versteijne","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08031-z","article-title":"Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): Study protocol for a nationwide multicenter randomized controlled trial","volume":"21","author":"Janssen","year":"2021","journal-title":"BMC Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1148\/radiol.2019182867","article-title":"LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium\u2013enhanced MRI","volume":"292","author":"Lee","year":"2019","journal-title":"Radiology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-2036.2005.02691.x","article-title":"Systematic review: The model for end-stage liver disease--should it replace Child-Pugh\u2019s classification for assessing prognosis in cirrhosis?","volume":"22","author":"Cholongitas","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/jmri.23731","article-title":"Magnetic resonance elastography of liver: Technique, analysis, and clinical applications","volume":"37","author":"Venkatesh","year":"2013","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jhep.2018.02.026","article-title":"Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes","volume":"69","author":"Lee","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/hep.28643","article-title":"The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.suronc.2019.10.006","article-title":"Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium","volume":"33","author":"Degroote","year":"2020","journal-title":"Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/jco.2016.34.4_suppl.348","article-title":"Gemcitabine (G) + nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review","volume":"34","author":"Chan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-015-0025-y","article-title":"Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity","volume":"4","author":"Zhang","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e15202","DOI":"10.1200\/jco.2014.32.15_suppl.e15202","article-title":"Gemcitabine plus nab-paclitaxel as second line and beyond for metastatic pancreatic cancer (MPC): A single institution retrospective analysis","volume":"32","author":"Zaniboni","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"556","DOI":"10.21037\/jgo.2017.01.23","article-title":"Gemcitabine\/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic\/advanced pancreatic cancer\u2014Retrospective analysis of response","volume":"8","author":"Nguyen","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/bjc.2015.328","article-title":"Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: An AGEO prospective multicentre cohort","volume":"113","author":"Portal","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/j.clcc.2018.03.003","article-title":"Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience","volume":"17","author":"Zhang","year":"2018","journal-title":"Clin. Color. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/jco.2016.34.4_suppl.397","article-title":"Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)\/FOLFOX(FX) and gemcitabine + nab-paclitaxel (NabG)","volume":"34","author":"Schmidt","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"806","DOI":"10.21037\/jgo.2018.06.08","article-title":"Retrospective analysis of efficacy and safety of gemcitabine based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX","volume":"9","author":"Camandaroba","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial","volume":"387","author":"Li","year":"2016","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: A Randomised Phase III Study of Fluorouracil\/Leucovorin WITH or without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy","volume":"34","author":"Gill","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2019.37.4_suppl.191","article-title":"Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program","volume":"37","author":"Pishvaian","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.2019.37.15_suppl.4014","article-title":"Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513","volume":"37","author":"Chiorean","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4605-1","article-title":"Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience","volume":"18","author":"Glassman","year":"2018","journal-title":"BMC Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","article-title":"Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative","volume":"24","author":"Pishvaian","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations","volume":"24","author":"Hu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted with Existing Drugs or Used as Biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion\u2013Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"viii713","DOI":"10.1093\/annonc\/mdy424.017","article-title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","volume":"29","author":"Demetri","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"12084","DOI":"10.1200\/JCO.2018.36.15_suppl.12084","article-title":"Incidence of Neuregulin1 (NRG1) gene fusions across tumor types","volume":"36","author":"Liu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/2159-8290.CD-18-0036","article-title":"NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer","volume":"8","author":"Heining","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-19-0191","article-title":"NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma","volume":"25","author":"Jones","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","article-title":"Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients with Pancreatic Adenocarcinoma","volume":"33","author":"Holter","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1002\/cncr.29664","article-title":"Identification of germline genetic mutations in patients with pancreatic cancer","volume":"121","author":"Kelsen","year":"2015","journal-title":"Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective Evaluation of Germline Alterations in Patients with Exocrine Pancreatic Neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO.18.01489","article-title":"Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion","volume":"37","author":"Stoffel","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2019.37.15_suppl.1582","article-title":"Unselected germline screening in pancreatic adenocarcinoma yields high rates of pathogenic and likely pathogenic variants (PV) in hereditary cancer susceptibility genes","volume":"37","author":"Cremin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_87","first-page":"439","article-title":"Pancreatic Adenocarcinoma, Version 2","volume":"19","author":"Tempero","year":"2021","journal-title":"2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2019.37.15_suppl.1506","article-title":"Ten-fold increase in genetic testing in pancreatic and metastatic prostate cancer with implementation of point of care (POC) testing","volume":"37","author":"Symecko","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1245\/s10434-018-6388-7","article-title":"Adjuvant Therapy Is Associated with Improved Survival in Resected Perihilar Cholangiocarcinoma: A Propensity Matched Study","volume":"25","author":"Nassour","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2019.37.15_suppl.4003","article-title":"ABC-06|A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin\/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced\/metastatic biliary tract cancers (ABC) previously-treated with cisplatin\/gemcitabine (CisGem) chemotherapy","volume":"37","author":"Lamarca","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/bjc.2016.446","article-title":"Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: Retrospective analysis of 321 patients","volume":"116","author":"Kim","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair\u2013Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JCO.2021.39.3_suppl.265","article-title":"Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement (abstract)","volume":"39","author":"Javle","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/5\/310\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:02:44Z","timestamp":1760166164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/5\/310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":99,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["curroncol28050310"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28050310","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2021,9,21]]}}}